Leukemic stem cells were hypothesized to play a critical role in acute myeloid leukemia relapse, but data to support this were lacking. In a recent study elegantly combining sequencing with functional xenograft assays, Shlush et al (2017) identified two distinct origins of leukemic relapse. They provided direct experimental evidence linking relapse to cancer stem cell clones already present before therapeutic intervention.